Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewCell biologyOncology Open Access | 10.1172/jci.insight.202630

EPHA2 and WNT reciprocally regulate MAPK-dependent gene expression in a pancreatic cancer model

Shawn R. Wadia,1 Changyuan Hu,2 Siddhi Patnaik,1 Shreya Sridharan,1 Roger J. Daly,2 David M. Virshup,1 and Babita Madan1

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Wadia, S. in: PubMed | Google Scholar |

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Hu, C. in: PubMed | Google Scholar

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Patnaik, S. in: PubMed | Google Scholar

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Sridharan, S. in: PubMed | Google Scholar

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Daly, R. in: PubMed | Google Scholar

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Virshup, D. in: PubMed | Google Scholar |

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore

2Cancer Program and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Find articles by Madan, B. in: PubMed | Google Scholar |

Published September 8, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.202630.
Copyright © 2026, Wadia et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published September 8, 2026 - Version history
View PDF
Abstract

Wnt signaling drives tumorigenesis in multiple cancers, in part through complex interactions with other oncogenic pathways including the MAPK cascade. In Wnt-addicted cancers, pharmacologic and genetic inhibition of Wnt signaling activates multiple receptor tyrosine kinases (RTKs), increases ERK phosphorylation and induces MAPK target gene expression, but the specific RTKs responsible for this MAPK hyperactivation are not known. Here we performed phosphotyrosine-targeted mass spectrometry, which revealed robust phosphorylation of EPHA2 and EGFR upon Wnt inhibition. Unexpectedly, we find that in xenografts, EPHA2 suppresses EGFR and ERK activation. Most notably, the increased ERK phosphorylation observed in EPHA2 KO tumors is transcriptionally inert, as there is no concomitant increase in MAPK target gene expression until concomitant Wnt inhibition. This suggests a Wnt-activated transcriptional repressor such as GATA3 that gates MAPK signaling in Wnt-high cancers. While Wnt-high KRAS-mutant cancers are resistant to erlotinib alone, adding Wnt inhibitor mitigates this resistance. Additionally, loss of EPHA2 enhances their sensitivity to both erlotinib and Wnt inhibitors. These studies therefore identify therapeutic vulnerabilities in Wnt-high tumors, even within traditionally EGFR inhibitor-resistant, RAS-mutant contexts. 

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View Supplemental Table S2 HCT116 pY

View Supplemental Table S3 RNA Seq

View Supplemental Table S1 pY Proteomics

View Supplemental Table S4 primer and sgRNA sequences

View

View Supplemental Table S5 Supporting data values

Version history
  • Version 1 (September 8, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts